Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

d, double-blind, placebo-controlled Phase 2 trial, 96% (351/364) elected to enter the 24-week open-label extension phase of the trial, and 92% (321/351) of those who entered completed it. Of those completing the extension phase, 78% (250/321) continue to receive LymphoStat-B in a long-term continuation study. The trial began in October 2003.

"We are encouraged that nearly all of the patients who completed the 52- week Phase 2 study chose to continue treatment in the 24-week extension phase," said William W. Freimuth, M.D., Ph.D., Vice President, Clinical Research -- Immunology, Rheumatology and Infectious Diseases, Human Genome Sciences. "Many of these patients began treatment more than three years ago and continue on treatment today. This provides us with a substantial body of data on the long-term effects of LymphoStat-B."

About the Phase 2 Trial Results

The primary objectives of the Phase 2 study were to evaluate the safety, tolerability and efficacy of LymphoStat-B plus standard of care, versus placebo plus standard of care. A total of 449 patients with active SLE were randomized to receive one of three different doses of LymphoStat-B or placebo (1, 4 or 10 mg/kg) administered intravenously over a 52-week treatment period, in addition to standard-of-care therapy. In the extension phase, all placebo patients received LymphoStat-B at a dose of 10 mg/kg, while patients in the LymphoStat-B 10 mg/kg treatment arm continued on the 10 mg/kg dose, and patients in the 1 mg/kg and 4 mg/kg LymphoStat-B treatment arms were offered the choice of continuing on the same dose or receiving LymphoStat-B at a dose of 10 mg/kg.

In June 2006, HGS reported the 52-week data from the Phase 2 trial of LymphoStat-B in patients with SLE. The 52-week results demonstrated that LymphoStat-B significantly reduced disease activity versus placebo in patients with serologically active SLE, exhibited clinically relevant biological activity, and appeared safe and well t
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:8/28/2015)... JACKSONVILLE, Fla. , Aug. 28, 2015  With ... reaching deadlier heights, Jacksonville ... Philip Hemphill is helping to explain why ... Fentanyl is approximately 40 to 50 times more potent ... by recreational users as heroin, the risk of death ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2Investigation Report on China's Pranoprofen Market, 2010-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Discovery Laboratories, Inc. (Nasdaq: DSCO) ... in the Journal of Neonatal-Perinatal Medicine, nearly ... about the exposure of newborn children to animal-derived medications. ... intensive care unit (NICU) who were interviewed in the ...
... Oct. 18, 2011 Bend Research Inc. ( www.bendresearch.com ... has announced a full schedule of events at the ... of Pharmaceutical Scientists (AAPS) in Washington, D.C. ... the last few years and we are now working ...
Cached Medicine Technology:New Study Shows Neonatologists and Parents of NICU Infants Share Concern Regarding Newborn Exposure to Animal-Derived Medications 2New Study Shows Neonatologists and Parents of NICU Infants Share Concern Regarding Newborn Exposure to Animal-Derived Medications 3Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition 2Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition 3
(Date:8/31/2015)... ... 31, 2015 , ... All birth control methods work best if used correctly ... among birth control methods. Moreover, no-scalpel vasectomy has many proven advantages with a lower ... vasectomy done because they are afraid of complications. , One Stop Medical Center ...
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has been in business ... marketing a doctor note service to be made available to all patients and ... each generated excuse, much less than the average daily pay of workers. ...
(Date:8/31/2015)... ... , ... The Marietta dentists and staff at Verde Pointe Dental ... and staff ran a 5K race, the Iron Horse for Enduring Hearts on August ... sponsored the event to help support projects with funding to increase understanding of clinical ...
(Date:8/30/2015)... ... August 31, 2015 , ... The acknowledgement from Caribbean Journal comes after Grace ... 2015. The island of Providenciales itself received a TripAdvisor Traveller's Choice Award in ... Bay is offering a special promotion for newlyweds and honeymooners to celebrate this amazing ...
(Date:8/30/2015)... Wilmington, DE (PRWEB) , ... August 31, 2015 ... ... an exhibitor at the AHCA/NCAL 66th Annual Convention & Expo October 5th & ... providers and organizations together, the AHCA/NCAL convention brings industry professionals from all over ...
Breaking Medicine News(10 mins):Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:Verde Pointe Dental Associates Runs a 5K for Enduring Hearts 2Health News:Grace Bay Beach Named a Top Beach Destination for Weddings 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2
... State ... Center Implants Two ... TUSTIN, Calif. and SYDNEY, April 22 Sunshine Heart ... announced today that The Ohio State University Medical Center in Columbus, ...
... Parks to hold second annual Walk-a-thon event THIS SUMMERNEW YORK, ... Six Flags, and Cure Kids Cancer have teamed up once ... its "A Walk In The Park" program. This unique ... properties April 26 through July 26 offering local neighborhoods a ...
... DC Raised Tobacco Taxes--WASHINGTON, April 22 According to a ... to be a slow year for tobacco control policies on ... steps that are needed to curb tobacco use and save ... Legislated Actions on Tobacco Issues or SLATI , ...
... NIJMEGEN, The Netherlands, April 22 InteRNA,Technologies ... have entered,into a research agreement to develop ... Under the research collaboration ... InteRNA,s unique lentiviral-based miRNA,overexpression library will be ...
... one serving a week, , , WEDNESDAY, April 22 (HealthDay News) ... acids appear to have a reduced risk of heart failure, ... U.S. and Swedish researchers followed nearly 40,000 Swedish men, ages ... their health outcomes. During that time, 597 men with no ...
... Advocacy Groups Join Together to Ask President Obama for a Greater ... ... TN (PRWEB) April 22, 2009 -- In recent days, both ... a greater voice in the healthcare reform debate. Understanding that ...
Cached Medicine News:Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 2Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 3Health News:Video: U.S. Announcement - First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 4Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 2Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 3Health News:Six Flags Friends Invites Guests to Help Cure Kids Cancer by Taking 'A Walk In The Park' 4Health News:New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies 2Health News:New American Lung Association Report Reveals States Failing to Enact Lifesaving Tobacco Control Policies 3Health News:InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer 2Health News:Fatty Fish May Cut Heart Failure Risk in Men 2Health News:Millennials Push For Seat at the Table on Healthcare Reform 2
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
Medicine Products: